{
  "pmcid": "10288861",
  "sha256": "6c954c561c3bd583c41c6126ac3c0ca3e1c33685632e093e5e5825dd9c93d605",
  "timestamp_utc": "2025-11-09T23:04:50.401043+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.211184210526316,
    "reading_ease": 21.673289473684235,
    "word_count": 304
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This phase II multicenter single-arm study"
      },
      "Participants": {
        "score": 2,
        "evidence": "enrolled patients with stage IB to select IIIB resectable NSCLC and Eastern Cooperative Oncology Group performance status 0/1"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received atezolizumab 1200 mg intravenously every 3 weeks for 2 cycles, followed by surgical resection."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluates the safety and efficacy of neoadjuvant atezolizumab in resectable NSCLC."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was major pathological response (MPR) in patients without EGFR/ALK alterations, assessed approximately 30 days post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From April 2017 to February 2020, 181 patients were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the primary efficacy population (n=143)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "the MPR rate was 20% (29/143; 95% CI, 14-28)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were recorded using Common Terminology Criteria for Adverse Events v.4.0."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}